Dianthus Therapeutics Inc

Dianthus Therapeutics Inc (DNTH) News & Events

$105.840

-5.408 (-5.11%)At close

DNTH News

DNTH Events

6/29 07:30

Dianthus Initiates Phase 3 Trial of Claseprubart

Dianthus announced initiation of the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis. EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial in approximately 195 participants with generalized Myasthenia Gravis who are acetylcholine receptor antibody positive.

6/12 15:30

Dianthus Therapeutics Reports 75% Response Rate for Claseprubart

In a regulatory filing, Dianthus Therapeutics reported more data from Part A of its Phase 3 CAPTIVTY study evaluating claseprubart in chronic inflammatory demyelinating polyneuropathy. The company said that claseprubart is "highly potent" classical pathway inhibitor with a roughly 8-week half-life, with clinical and in vitro head-to-head data supporting its potential for a more effective and convenient biologic with no boxed warning. Dianthus said it observed a 75% response rate from the first 40 participants to complete CAPTIVATE Part A, supporting best-in-disease potential, which is higher than the overall rate in the riliprubart Phase 2 at week 24. The company added that mean INCAT score change in responders was at -1.6 at last evaluable visit, and that claseprubart has consistently higher affinity and stronger potency in multiple head-to-head in vitro experiments.

6/12 12:30

Dianthus Stock Rises 7.7% to $82.37

Dianthus is up 7.7%, or $5.92 to $82.37.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started